Nemolizumab
Galderma
['nemolizumab', 'derm', 'galderma']
 @ wcd 2023: late-breaking phase iii results for nemolizumab monotherapy in prurigo nodularis show a significant proportion of itch-free patients by week 4 #aetoswire #business #businessnews 
AETOSWire provides timely, highly customized, and targeted press release distribution anywhere in the world.